Key Details
Price
$152.79Last Dividend
$1.24Beta
-0.09Events Calendar
Next earnings date:
Apr 15, 2025Recent quarterly earnings:
Jan 22, 2025Recent annual earnings:
Jan 22, 2025Next ex-dividend date:
Feb 18, 2025Recent ex-dividend date:
Nov 26, 2024Next split:
N/ARecent split:
June 13, 2001Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Johnson & Johnson (JNJ -0.47%) is a major player in the global healthcare industry. If the decision to invest in a company was based solely on its size, buying its stock would be an obvious choice.
We have just released a list of the 12 Best Defensive Stocks to Buy at the Moment. In this article, we will examine how Johnson & Johnson (NYSE:JNJ) compares to other top defensive stocks available for purchase. A significant factor affecting the current market mood is the recent decline in technology stocks, mainly caused by […]
Pomerantz LLP is looking into claims for investors of Johnson & Johnson ("J&J" or the "Company") (NYSE:JNJ) as of February 1, 2025. Investors who have concerns are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
Johnson & Johnson (JNJ -0.47%) has a varied healthcare business, making it a popular choice for investors seeking a reliable dividend stock for long-term investment. However, it has struggled with growth in recent times.
Johnson & Johnson (JNJ -0.47%) had a disappointing year in 2024, ranking among the lowest-performing stocks in the prestigious 30-company Dow Jones Industrial Average.
The U.S. Department of Health & Human Services might ask Johnson & Johnson for more than $1 billion to cover medical expenses paid by federal health agencies for patients claiming that the company's baby powder and other talc products led to their cancer, according to a government lawyer on Friday.
On January 22, Johnson & Johnson announced its financial results for the fourth quarter of 2024, which exceeded my expectations once more. The sales from its oncology division reached $5.5 billion, marking a 19% rise compared to the same quarter in 2023. Additionally, the company anticipates a 2% to 3% growth in operational sales for 2025, with adjusted diluted earnings per share expected to be between $10.50 and $10.70, indicating single-digit growth.
We have just released a list of 12 Safe Stocks to Invest in for the Long Term in 2025. In this article, we will examine how Johnson & Johnson (NYSE:JNJ) compares to other safe stocks for long-term investment in 2025. The US stock market is frequently seen as a […]
The new trading year is beginning, and investors may want to make it as successful as 2024 or even better. To achieve this, it's important to start off well, which means the first quarter should show strong performance to give portfolios the energy and space to take on more ambitious growth projects later in the year.
Analysts at Jefferies think that the recent quarterly sales numbers for Johnson & Johnson's esketamine nasal spray show that psychedelics could be successful in the mental health market. In the fourth quarter, sales of Spravato increased by 5% compared to the previous quarter, reaching $297 million due to higher demand from doctors and patients.
FAQ
- What is the primary business of Johnson & Johnson?
- What is the ticker symbol for Johnson & Johnson?
- Does Johnson & Johnson pay dividends?
- What sector is Johnson & Johnson in?
- What industry is Johnson & Johnson in?
- What country is Johnson & Johnson based in?
- When did Johnson & Johnson go public?
- Is Johnson & Johnson in the S&P 500?
- Is Johnson & Johnson in the NASDAQ 100?
- Is Johnson & Johnson in the Dow Jones?
- When was Johnson & Johnson's last earnings report?
- When does Johnson & Johnson report earnings?
- Should I buy Johnson & Johnson stock now?